Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS

    22 Citations (Scopus)

    Abstract

    A capillary electrophoresis inductively coupled plasma mass spectrometry method for separation of free cisplatin from liposome-encapsulated cisplatin and protein-bound cisplatin was developed. A liposomal formulation of cisplatin based on PEGylated liposomes was used as model drug formulation. The effect of human plasma matrix on the analysis of liposome-encapsulated cisplatin and intact cisplatin was studied. The presence of 1 % of dextran and 4 mM of sodium dodecyl sulfate in HEPES buffer was demonstrated to be effective in improving the separation of liposomes and cisplatin bound to proteins in plasma. A detection limit of 41 ng/mL of platinum and a precision of 2.1 % (for 10 μg/mL of cisplatin standard) were obtained. Simultaneous measurements of phosphorous and platinum allows the simultaneous monitoring of the liposomes, liposome-encapsulated cisplatin, free cisplatin and cisplatin bound to plasma constituents in plasma samples. It was demonstrated that this approach is suitable for studies of the stability of liposome formulations as leakage of active drug from the liposomes and subsequent binding to biomolecules in plasma can be monitored. This methodology has not been reported before and will improve characterization of liposomal drugs during drug development and in studies on kinetics. [Figure not available: see fulltext.]

    Original languageEnglish
    JournalAnalytical and Bioanalytical Chemistry
    Volume405
    Issue number6
    Pages (from-to)1845-1854
    ISSN1618-2642
    DOIs
    Publication statusPublished - Feb 2013

    Fingerprint

    Dive into the research topics of 'Metallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS'. Together they form a unique fingerprint.

    Cite this